BioSight
Companies
Keros Therapeutics, Inc. logo

KROS

NASDAQLEXINGTON, MA
Keros Therapeutics, Inc.

Keros Therapeutics develops protein-based drugs targeting rare diseases, including Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and myelodysplastic syndromes. The lead candidate, rinvatercept (KER-065), is in early-stage clinical testing, with a Phase 2 trial planned in muscular dystrophy patients and regulatory discussions underway for another Phase 2 trial in ALS patients. A partnered program, elritercept (KER-050), is being advanced into Phase 3 testing by Takeda Pharmaceuticals.

Price history not yet available for KROS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar